This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
|Videos|August 23, 2022
Navigating monkeypox in children
Author(s)Morgan Ebert, Executive Editor
Craig Shapiro, MD, pediatric infectious disease specialist at Nemours Children's Hospital, sits down to discuss the recent uptick in pediatric monkeypox cases and explains what to do if you suspect your patient to have monkeypox.
Advertisement
*Editor's Note: Please note at the time of the interview there were 5 reported pediatric monkeypox cases. That number has since risen.
Advertisement
Related to this article
XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.
Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.
Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.
New evidence supports influenza, COVID-19, and RSV immunizations for reducing severe respiratory illness and hospitalization.
CDC's 2025 NIS-Teen data show HPV vaccine coverage flat for a fourth year, with rural adolescents 12 points behind urban peers in receiving ≥1 dose.
The AAP's 2026-2027 policy recommends universal vaccination for infants 6-23 months and a risk-based single dose for children 2-18 years.
AAP guidance expands RSV immunization eligibility for children aged 8 through 19 months at high risk of severe disease.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial
3
FDA approves levacetylleucine as first treatment for ataxia in ataxia-telangiectasia
4
How Breast Milk Shapes Gut Microbiome Signaling and Immunity
5